Back to Media Room
 
Malaysian Reserve, June 12, 2008

BiotechCorp expects to acquire 3 tech platforms

MALAYSIAN Biotechnology Corp (BiotechCorp) plans to acquire three technology platforms to expedite development of the local biotechnology industry, CEO Datuk Iskandar Mizal Mahmood said yesterday.

Speaking to reporters after releasing BiotechCorp’s inaugural annual report for 2007, Iskandar said the company was currently conducting a due diligence study and hoped to conclude the acquisitions within the third or final quarter of this year.

He said RM51 million had been allocated for the acquisitions, adding that BiotechCorp used RM3 million for its first acquisition of a worldwide licence for a nanotechnology platform from France in November 2007.

Iskandar said the new technology platforms would focus on three areas – agricultural biotechnology, industrial biotechnology, and healthcare biotechnology.

BiotechCorp, funded by the government, was established to ensure that the national biotechnology objectives and strategies were fully deployed.

Currently, there are 56 BioNexus status companies, of which 23 are in healthcare biotechnology, 17 in agriculture biotechnology, 14 in industrial biotechnology and two in bioinformatics.

According to BiotechCorp, the total investment to date from the 56 companies is RM1.3 billion.

On the annual report, Iskandar said grants amounting to RM6.25 million had been approved for four BioNexus companies in 2007, with 14 more applications for grants amounting to RM33 million awaiting approval.

“BiotechCorp’s initiatives are in line with the National Biotechnology Policy and master plan launched in 2005. We are always prudent in our spending and exercise due diligence when drafting the annual business plan as well as the budget,” he said.

“This was evident in 2007 when BiotechCorp reduced its operating expenses by RM8 million. We broke even in our operating budget,” he added.

BiotechCorp’s operating profit was RM377, 176 in 2007, compared to a loss of RM24.61 million the previous year. Net profit amounted to RM360, 877 from a previous net loss of RM24.63 million. – Bernama
Home | Biotech In Malaysia | About Us | One Stop Centre | The BioNexus Network | Grants & Programmes | Events |
Media Room
| Contact Us | Useful Links | Disclaimer